220 related articles for article (PubMed ID: 11915742)
1. [A case of subacute transient cerebral dysfunction in a osteosarcoma patient following high-dose methotrexate].
Yamada K; Takahashi M; Yoshida M
Gan To Kagaku Ryoho; 2002 Mar; 29(3):469-72. PubMed ID: 11915742
[TBL] [Abstract][Full Text] [Related]
2. [Toxicosis of high-dose methotrexate (HD-MTX) for osteosarcoma, cured with treatment by leucovorin (LV) rescue and hemoperfusion--a case report].
Kobayashi H; Morita T; Hirata Y; Kato T; Okada Y; Sato T
Gan To Kagaku Ryoho; 2000 Mar; 27(3):475-8. PubMed ID: 10740644
[TBL] [Abstract][Full Text] [Related]
3. [The importance of dose intensity in preoperative chemotherapy for osteosarcoma--retrospective analysis of a short intensive chemotherapy regimen preoperatively using high-dose methotrexate and cisplatinum].
Takahashi M; Katagiri H; Sato K; Sugiura H; Yamamura S; Fukaya N; Nakanishi K
Gan To Kagaku Ryoho; 1994 Mar; 21(4):459-64. PubMed ID: 8129386
[TBL] [Abstract][Full Text] [Related]
4. Toxic encephalopathy and delayed MTX clearance after high-dose methotrexate therapy in a child homozygous for the MTHFR C677T polymorphism.
Müller J; Kralovánszky J; Adleff V; Pap E; Németh K; Komlósi V; Kovács G
Anticancer Res; 2008; 28(5B):3051-4. PubMed ID: 19031955
[TBL] [Abstract][Full Text] [Related]
5. Transient cerebral dysfunction following chemotherapy for osteogenic sarcoma.
Allen JC; Rosen G
Ann Neurol; 1978 May; 3(5):441-4. PubMed ID: 310278
[TBL] [Abstract][Full Text] [Related]
6. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma.
Crews KR; Liu T; Rodriguez-Galindo C; Tan M; Meyer WH; Panetta JC; Link MP; Daw NC
Cancer; 2004 Apr; 100(8):1724-33. PubMed ID: 15073863
[TBL] [Abstract][Full Text] [Related]
7. [Neo-adjuvant therapy in childhood osteogenic sarcoma: a pilot study of selective postoperative chemotherapy based on response to preoperative high-dose methotrexate].
Sasaki K; Matsuoka H; Murakami T; Fujimoto T; Takayanagi F; Sawai K; Niwa J; Hara K
Gan To Kagaku Ryoho; 1986 May; 13(5):1837-45. PubMed ID: 3486634
[TBL] [Abstract][Full Text] [Related]
8. Acute transient cerebral toxicity associated with administration of high-dose methotrexate.
Mittal R; Mottl H; Nemec J
Med Princ Pract; 2005; 14(3):202-4. PubMed ID: 15863997
[TBL] [Abstract][Full Text] [Related]
9. Methotrexate levels and outcome in osteosarcoma.
Zelcer S; Kellick M; Wexler LH; Shi W; Sankaran M; Lo S; Healey J; Huvos AG; Meyers PA; Gorlick R
Pediatr Blood Cancer; 2005 Jun; 44(7):638-42. PubMed ID: 15704189
[TBL] [Abstract][Full Text] [Related]
10. Progression of osteosarcoma after high-dose methotrexate: over-rescue by folinic acid.
Cohen IJ
Pediatr Hematol Oncol; 2003 Dec; 20(8):579-81. PubMed ID: 14578026
[TBL] [Abstract][Full Text] [Related]
11. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
[TBL] [Abstract][Full Text] [Related]
12. Successful desensitization to high-dose methotrexate after systemic anaphylaxis.
Davis KA; Williams P; Walker JC
Ann Allergy Asthma Immunol; 2003 Jan; 90(1):87-9. PubMed ID: 12546343
[TBL] [Abstract][Full Text] [Related]
13. Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression.
Patiño-García A; Zalacaín M; Marrodán L; San-Julián M; Sierrasesúmaga L
J Pediatr; 2009 May; 154(5):688-93. PubMed ID: 19159907
[TBL] [Abstract][Full Text] [Related]
14. Transient encephalopathy following high-dose methotrexate.
Lee AC; Li CH; Wong YC
Med Pediatr Oncol; 2003 Jul; 41(1):101. PubMed ID: 12764767
[No Abstract] [Full Text] [Related]
15. Anaphylactoid reaction to high-dose methotrexate and successful desensitization.
Oulego-Erroz I; Maneiro-Freire M; Bouzón-Alejandro M; Vázquez-Donsión M; Couselo JM
Pediatr Blood Cancer; 2010 Sep; 55(3):557-9. PubMed ID: 20533520
[TBL] [Abstract][Full Text] [Related]
16. Outpatient high-dose methotrexate: proceed with extreme caution, if at all.
Womer RB
Pediatr Blood Cancer; 2010 Dec; 55(7):1250-1. PubMed ID: 20981687
[No Abstract] [Full Text] [Related]
17. [Carboxypeptidase-G2 administration after high-dose methotrexate. Treatment and drug interactions].
Cózar Olmo JA; Martínez Colmenero C; Peláez Pleguezuelos I; Leiva Gea I; López García AB; de la Cruz Moreno J
An Pediatr (Barc); 2009 Sep; 71(3):230-4. PubMed ID: 19617010
[TBL] [Abstract][Full Text] [Related]
18. Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.
Nowicki TS; Bjornard K; Kudlowitz D; Sandoval C; Jayabose S
J Pediatr Hematol Oncol; 2008 Dec; 30(12):950-2. PubMed ID: 19131789
[TBL] [Abstract][Full Text] [Related]
19. No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma.
Bacci G; Loro L; Longhi A; Bertoni F; Bacchini P; Versari M; Picci P; Serra M
Anticancer Drugs; 2006 Apr; 17(4):411-5. PubMed ID: 16549998
[TBL] [Abstract][Full Text] [Related]
20. Effective removal of methotrexate by high-flux hemodialysis.
Saland JM; Leavey PJ; Bash RO; Hansch E; Arbus GS; Quigley R
Pediatr Nephrol; 2002 Oct; 17(10):825-9. PubMed ID: 12376811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
